PT  - JOURNAL ARTICLE
ED  - ,
TI  - Tadalafil for benign prostatic hyperplasia
AID  - 10.1136/dtb.2013.8.0199
DP  - 2013 Aug 01
TA  - Drug and Therapeutics Bulletin
PG  - 93--96
VI  - 51
IP  - 8
4099  - http://dtb.bmj.com/content/51/8/93.short
4100  - http://dtb.bmj.com/content/51/8/93.full
SO  - Drug Ther Bull2013 Aug 01; 51
AB  - Tadalafil is a phosphodiesterase type-5 (PDE5) inhibitor licensed for the treatment of erectile dysfunction (ED) in adult males (Cialis—Lilly) and for the management of pulmonary arterial hypertension (Adcirca—Lilly).1 The 5mg tablet was licensed in November 2012 for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH) in adult males (Cialis 5mg—Lilly).2 In this article, we consider the evidence for tadalafil and how its use fits with current management strategies for BPH.